|Bid||62.00 x 4000|
|Ask||62.01 x 1300|
|Day's range||61.38 - 62.05|
|52-week range||57.17 - 74.12|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||18.96|
|Forward dividend & yield||2.92 (4.78%)|
|Ex-dividend date||14 Sept 2022|
|1y target est||N/A|
FOSTER CITY, Calif., August 09, 2022--Gilead Sciences, Inc. (Nasdaq: GILD), GLAAD, the Human Rights Campaign (HRC), the National Black Justice Coalition (NBJC), the National Center for Lesbian Rights (NCLR) and NMAC today announced immediate action in response to the emerging monkeypox virus (MPV) outbreak, which is disproportionately impacting the LGBTQ+ community, particularly men who have sex with men (MSM), as well as those who are living with HIV. Gilead will provide up to $5 million in glo
FOSTER CITY, Calif. & OXFORD, England, August 04, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.
FOSTER CITY, Calif., August 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2022.